Skip to main content
Premium Trial:

Request an Annual Quote

Protagen Signs Biomarker Discovery Deal with Pfizer

NEW YORK (GenomeWeb News) – Protagen said today that it has entered a collaboration agreement with Pfizer to use its SeroTag technology to identify biomarkers in support of Pfizer's drug development work.

Specifically, the collaboration aims to identify markers for stratifying patient cohorts or predicting patient response to a novel autoimmune disease drug being developed by Pfizer.

Protagen's SeroTag platform uses Luminex-based screens of patient sera against large sets of proteins to identify autoantibody signatures that are prognostic or diagnostic for various conditions. According to the company, it has successfully used the platform for biomarker discovery in autoimmune diseases including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus.

In addition to Pfizer, Protagen counts among its customers pharma firms including Biogen Idec, SuppreMol, and Bayer.

"The current agreement shows that the SeroTag process ... is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases," Protagen CEO Stefan Müllner said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.